Micro Interventional Devices, Inc. Initiates “First-in-Man” Clinical Study of Permaseal™
STASIS Clinical Study Begins in Europe
Top-line Data Expected by Year End
NEWTOWN, Pa., Sept. 9, 2014 /PRNewswire/ — Micro Interventional Devices, Inc. (MID) reports the first successful clinical case using its Permaseal Cardiac Access and Closure technology. This new technology simplifies minimally invasive aortic valve replacement procedures. The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe.
This article appeared in the September 9, 2014 edition of Philadelphia Business Journal, to continue reading click here: http://www.bizjournals.com/philadelphia/prnewswire/press_releases/Georgia/2014/09/09/NE07701?ana=prnews